The first patient has been dosed with PMCC-COE-KMA, an investigational CAR T-cell therapy being developed by Peter MacCallum Cancer Centre’s Centre of Excellence in Cellular Immunotherapy (CoE) and licensed by Australian biotechnology company HaemaLogiX. The KOALA trial will evaluate the safety and efficacy of PMCC-COE-KMA in patients… Read More
Dr Rosanne Dunn, Co-Founder and Chief Scientific Officer at HaemaLogiX, explores how discovery of a new class of tumour‑specific antigens is transforming how we treat plasma cell dyscrasias. For more than two decades, progress in multiple myeloma has been marked by sustained advances in drug development… Read More
Biotechnology company HaemaLogiX has begun patient enrolment for a Phase I study evaluating a therapy for multiple myeloma. The KOALA study is a Phase I dose‑escalation trial assessing the safety and preliminary efficacy of KMCAR T‑cell, a novel autologous CAR‑T therapy targeting the Kappa Myeloma Antigen (KMA), a tumour‑specific receptor… Read More
News round-up for 16 – 20 March February by Bruno Quinney, Content Team at DDW. This week, a pioneering method is being used to make drugs for Parkinson’s disease. Elsewhere, advances have been made in both research and trials for common cancers. The top stories: Edinburgh team… Read More
New research published in the Clinical Lymphoma, Myeloma & Leukemia journal has confirmed that Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) are promising therapeutic targets for the treatment of multiple myeloma. These antigens are present on malignant plasma cells but… Read More
